Assessment of Median and Mean Survival Time in Cancer Clinical Trials
JAMA Network Open · 03.04.2023 · 6 (4) · e236498
DOI: 10.1001/jamanetworkopen.2023.6498 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 03.04.2023. Verfasst von Ananya Das und 6 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Houston. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
This cohort study assesses the relative stability of median and mean survival time estimates reported in cancer clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- The University of Texas MD Anderson Cancer Center, Houston.
- Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Azrieli Faculty of Medicine, Bar-Ilan University, Ramat Gan, Israel.
- Insitro, South San Francisco, California.
- Department of Health Research and Policy, Stanford University, Stanford, California.
Förderung
- NHLBI NIH HHS
- NCI NIH HHS
Zitieren
APA
Das, A., Lin, T. A., Lin, C., Meirson, T., McCaw, Z. R., Tian, L., & Ludmir, E. B. (2023). Assessment of Median and Mean Survival Time in Cancer Clinical Trials. JAMA Network Open, 6(4), e236498. https://doi.org/10.1001/jamanetworkopen.2023.6498
Vancouver
Das A, Lin TA, Lin C, Meirson T, McCaw ZR, Tian L, et al. Assessment of Median and Mean Survival Time in Cancer Clinical Trials. JAMA Network Open. 2023;6(4):e236498. doi:10.1001/jamanetworkopen.2023.6498
BibTeX
@article{Das2023,
author = {Das, Ananya and Lin, Timothy A and Lin, Christine and Meirson, Tomer and McCaw, Zachary R and Tian, Lu and Ludmir, Ethan B},
title = {Assessment of Median and Mean Survival Time in Cancer Clinical Trials},
journal = {JAMA Network Open},
year = {2023},
volume = {6},
number = {4},
pages = {e236498},
doi = {10.1001/jamanetworkopen.2023.6498}
}
EUVIMED